Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 7, 2009

BioLife to Produce Custom Biopreservation Media for Centocor

  • BioLife Solutions signed a license and custom cGMP manufaturing agreement with Centocor R&D. The company will produce a variant of its serum-free and protein-free CryoStor biopreservation media product, which is formulated with a reduced concentration of 2% DMSO.

    BioLife specializes in the development of patented hypothermic storage/transport and cryopreservation media products for cells, tissues, and organs. The company claims its GMP products are serum/protein-free and preformulated to reduce delayed-onset cell damage and death.

    In November BioLife was granted a Japanese patent covering claims related to protecting cells from injury and death caused by cold temperatures used in biopreservation. BioLife was previously granted equivalent U.S. and European patent protection for the IP. In September Sigma Aldrich negotiated a nonexclusive distribution agreement for BioLife’s HypoThermosol and CryoStor products.


Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »